AbCellera Biologics Inc. Common Shares (ABCL)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Applying Graham's insistence on demonstrated earning power and Buffett's preference for durable franchises, I see AbCellera as a speculative clinical-stage biotechnology company rather than a proven business. The stock closed at $12.61 on 2026-10-13, for a $3.9 billion market capitalization. At that close, FairStock calculations show a negative P/E of -23.35, a P/B of 4.32, negative EPS of -$0.54, ROE of -17.30%, and ROCE of -10.39%. In the quarter ended 2026-06-30 (fiscal Q2 2026), revenue was $4.0 million and net loss was $55.4 million, or -$0.18 per diluted share. The prior quarter, ended 2026-03-31 (fiscal Q1 2026), had revenue of $8.3 million and a net loss of $43.2 million, or -$0.14 per diluted share. A year earlier, the quarter ended 2025-06-30 (fiscal Q2 2025), had revenue of $17.1 million and a net loss of $34.7 million, or -$0.12 per diluted share. Revenue is shrinking and losses are widening. In fiscal year 2025, revenue was $75.1 million with a net loss of $146.4 million, or -$0.49 per share; fiscal year 2024 revenue was $28.8 million with a net loss of $162.9 million, or -$0.55; fiscal year 2023 revenue was $38.0 million with a net loss of $146.4 million, or -$0.51. The balance sheet has low debt—D/E 0.15—and FairStock's Altman Z-Score of 5.93 suggests low near-term bankruptcy risk, but trailing free cash flow is -$119.7 million and FCF yield is -3.1%. A Piotroski F-score of 3/9 confirms weak fundamentals. The 52-week range of $2.74 to $15.02 shows wild speculation. FairStock tags it TURNAROUND — Loss in latest year after earlier profits—yet filed annual results show continuing losses. With no positive earnings in the filed figures, there is no margin of safety; value depends on clinical success.

In plain English: AbCellera is a healthcare company that develops antibody-based medicines. Its main drug candidates are still in human testing, and the business is losing money: in the quarter ended 2026-06-30, revenue was $4.0 million and the net loss was $55.4 million. At $12.61 on 2026-10-13, the price looks expensive compared with today's small sales and losses, so the shares mostly reflect hopes for future drugs rather than current results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer